Abbott Labs To Buy Facet Biotech For $450M

Law360, New York (March 11, 2010, 5:18 PM EST) -- Abbott Laboratories Inc. has said it will purchase Facet Biotech Inc. for $450 million as part of a plan to enhance its pharmaceutical pipeline and strengthen its business in immunology and oncology drugs.

Illinois-based Abbott will offer $27 per share in cash for a total purchase price of $722 million, which will be adjusted to account for about $272 million in Facet's projected cash and marketable securities at closing, the companies said Tuesday.

The deal will give Abbott access to daclizumab, a biologic intended to treat...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.